Online Tool for the Assessment of the Burden of COVID-19 in Patients: Development Study

Noort, Esther van; Claessens, Danny; Moor, Catharina C.; Berg, Carlijn A L Van Den; Kasteleyn, Marise J.; Veen, Johannes In ‘t; Schayck, Onno C. P. van; Chavannes, Niels H.

doi:10.2196/22603

Cited by 3 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different health‐related quality of life and other PROMs were collected at discharge, 6 weeks, 3 months and after 6 months. Included questionnaires were the EuroQol five dimensions 5‐level questionnaire (EQ‐5D‐5L), 15 the fatigue assessment scale (FAS) 16 the global rating of change (GRoC) 17 and the online tool for the assessment of the burden of COVID‐19 (ABCoV tool) 18 . All results are visualized in graphs and directly available for patients and healthcare team (Figure 1 and Figure S2 in the Supporting Information).…”

Section: Methodsmentioning

confidence: 99%

Home monitoring of lung function, symptoms and quality of life after admission with COVID‐19 infection: The HOMECOMIN' study

Nakshbandi¹,

Moor²,

Nossent

et al. 2022

Respirology

View full text Add to dashboard Cite

Background and objective To develop targeted and efficient follow‐up programmes for patients hospitalized with coronavirus disease 2019 (COVID‐19), structured and detailed insights in recovery trajectory are required. We aimed to gain detailed insights in long‐term recovery after COVID‐19 infection, using an online home monitoring programme including home spirometry. Moreover, we evaluated patient experiences with the home monitoring programme. Methods In this prospective multicentre study, we included adults hospitalized due to COVID‐19 with radiological abnormalities. For 6 months after discharge, patients collected weekly home spirometry and pulse oximetry measurements, and reported visual analogue scales on cough, dyspnoea and fatigue. Patients completed the fatigue assessment scale (FAS), global rating of change (GRC), EuroQol‐5D‐5L (EQ‐5D‐5L) and online tool for the assessment of burden of COVID‐19 (ABCoV tool). Mixed models were used to analyse the results. Results A total of 133 patients were included in this study (70.1% male, mean age 60 years [SD 10.54]). Patients had a mean baseline forced vital capacity of 3.25 L (95% CI: 2.99–3.44 L), which increased linearly in 6 months with 19.1% (Δ0.62 L, p < 0.005). Patients reported substantial fatigue with no improvement over time. Nevertheless, health status improved significantly. After 6 months, patients scored their general well‐being almost similar as before COVID‐19. Overall, patients considered home spirometry useful and not burdensome. Conclusion Six months after hospital admission for COVID‐19, patients' lung function and quality of life were still improving, although fatigue persisted. Home monitoring enables detailed follow‐up for patients with COVID‐19 at low burden for patients and for the healthcare system.

show abstract

Section: Methodsmentioning

confidence: 99%

Home monitoring of lung function, symptoms and quality of life after admission with COVID‐19 infection: The HOMECOMIN' study

Nakshbandi¹,

Moor²,

Nossent

et al. 2022

Respirology

View full text Add to dashboard Cite

show abstract

“…This tool is a patient-reported outcome measure (PROM) designed to assist in individualized medical decision-making within a complex and changing healthcare environment. The ABCC tool is an evolution of the Assessment of Burden of COPD (ABC) tool developed in 2014 [ 13 ] and has been expanded to cover various chronic conditions beyond COPD, including asthma, type 2 diabetes mellitus (T2DM), heart failure [ 6 ], and post-COVID syndrome [ 8 ].…”

Section: Interventionsmentioning

confidence: 99%

“…This tool has been successfully implemented in the Netherlands, demonstrating its potential benefits in chronic disease management [ 7 ]. It is currently available through various providers, including hospital information systems and personal health environments [ 8 ]. However, its implementation in other regions, such as South Tyrol, has yet to be explored.…”

Section: Introductionmentioning

confidence: 99%

A cluster-randomized study to evaluate the effectiveness and cost-effectiveness of the Assessment of Burden of Chronic Conditions (ABCC) tool in South Tyrolean primary care for patients with COPD, asthma, type 2 diabetes, and heart failure: the ABCC South Tyrol study

Wiedermann,

Marino,

Mahlknecht

et al. 2024

Trials

View full text Add to dashboard Cite

Background Chronic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, type 2 diabetes, and heart failure, often coexist and contribute to a significant burden on individuals and health systems. The Assessment of Burden of Chronic Conditions (ABCC) tool, already in routine clinical use in the Netherlands, aims to comprehensively assess and visualize disease burden, stimulate self-management, and encourage shared decision-making. This study aims to validate the German and Italian versions of the ABCC tool and evaluate its effectiveness and cost-effectiveness in the South Tyrolean Primary Care setting. Methods This is a cluster-randomized study involving approximately 400 patients with COPD, asthma, type 2 diabetes, and heart failure who received care from the South Tyrolean General Practices. Initially, the ABCC tool will be translated into German and Italian and validated. Subsequently, half of the participants will use the validated ABCC tool for patient-reported outcome measurement assessments, while the other half will receive usual care. The primary outcome measure is the change in the patients’ perception of the quality of care after 18 months. The secondary outcomes included changes in quality of life, self-management behavior, and healthcare utilization. The missing data will be managed using multiple imputations. Additionally, a cost-effectiveness analysis that considers the direct medical costs reimbursed by the National Health Service will be conducted. Discussion This study provides insights into the application, validation, and efficacy of the ABCC tool in the South Tyrolean healthcare context. The tool’s potential to enhance person-centered care, improve the quality of life, and possibly reduce healthcare costs could greatly contribute to sustainable healthcare. The challenges of implementation, such as software integration and the use of an EU data platform, will provide lessons for future international patient care data management. Trial registration ISRCTN registry, ISRCTN13531607. Registered on August 23, 2023.

show abstract

“…NHS England Digital offers the COVID-19 Clinical Risk Assessment Tool, powered by QCovid®, which assists clinicians in understanding the risk level of individuals for COVID-19-related mortality following infection [ 58 ]. Another valuable resource is the Online Tool for the Assessment of the Burden of COVID-19 in Patients, developed to evaluate the long-term impact of COVID-19 on patients [ 59 ]. Furthermore, Queensland Health provides the COVID-19 Clinical Screening and Risk Assessment tool, which aids in assessing the clinical and symptom risk of COVID-19 in patients [ 60 ].…”

Section: Reviewmentioning

confidence: 99%

A Comprehensive Review on Navigating the Neurological Landscape of COVID-19: Insights Into Etiopathogenesis and Clinical Management

Chavhan,

Wanjari,

Kumar

et al. 2024

Cureus

View full text Add to dashboard Cite

The coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a global health crisis with significant neurological implications. While initially characterized by respiratory symptoms, COVID-19 has been increasingly recognized for its diverse neurological manifestations, including encephalopathy, stroke, peripheral neuropathies, and neuropsychiatric disorders. Understanding the neurological landscape of COVID-19 is essential for elucidating its pathophysiology, optimizing clinical management, and improving patient outcomes. This comprehensive review provides insights into the etiopathogenesis, clinical manifestations, diagnostic approaches, management strategies, and prognostic implications of neurological involvement in COVID-19. Mechanistic insights highlight the multifactorial nature of neurological complications involving direct viral invasion, immune-mediated mechanisms, and thrombotic events. Diagnostic challenges underscore the importance of a multidisciplinary approach to patient care, while management strategies emphasize early recognition and appropriate intervention. Long-term neurological sequelae and prognostic factors are also examined, emphasizing the need for comprehensive follow-up and rehabilitation services. Finally, recommendations for future research prioritize efforts to elucidate underlying mechanisms, identify biomarkers, and evaluate rehabilitative interventions. By addressing these challenges, we can better understand and mitigate the neurological consequences of the ongoing COVID-19 pandemic.

show abstract

Online Tool for the Assessment of the Burden of COVID-19 in Patients: Development Study

Cited by 3 publications

References 16 publications

Home monitoring of lung function, symptoms and quality of life after admission with COVID‐19 infection: The HOMECOMIN' study

Home monitoring of lung function, symptoms and quality of life after admission with COVID‐19 infection: The HOMECOMIN' study

A cluster-randomized study to evaluate the effectiveness and cost-effectiveness of the Assessment of Burden of Chronic Conditions (ABCC) tool in South Tyrolean primary care for patients with COPD, asthma, type 2 diabetes, and heart failure: the ABCC South Tyrol study

A Comprehensive Review on Navigating the Neurological Landscape of COVID-19: Insights Into Etiopathogenesis and Clinical Management

Contact Info

Product

Resources

About